Promising results for new lipid-modifying drug

GPs could be handed a new class of treatments for cardiovascular disease after an experimental drug was found to improve lipid profiles in at-risk patients.

Evacetrapib reduces levels of LDL cholesterol (right) and increases levels of HDL cholesterol (left). | SCIENCE PHOTO LIBRARY
Evacetrapib reduces levels of LDL cholesterol (right) and increases levels of HDL cholesterol (left). | SCIENCE PHOTO LIBRARY

Evacetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, substantially increased high-density lipoprotein (HDL) cholesterol whilst decreasing low-density lipoprotein (LDL) cholesterol, in a trial published in the Journal of the American Medical Association.

In the trial, a team from the Cleveland Clinic in Ohio, US randomised 398 patients with dyslipidaemia to receive either placebo, evacetrapib (30mg, 100mg or 500mg daily), or a statin with or without evacetrapib (100mg daily).

After 12 weeks, patients receiving evacetrapib as monotherapy experienced average reductions in LDL cholesterol of up to 36%, or 1.32mmol/L. Additionally, those on the highest dose of evacetrapib saw a rise in HDL cholesterol of up to 129%, or 1.69mmol/L.

By contrast, LDL cholesterol rose by 4% and HDL cholesterol fell by 3% in the placebo group.

LDL cholesterol decreased to a greater extent among patients receiving evacetrapib 100mg in combination with statin therapy, although researchers found no additional rise in HDL cholesterol.

They concluded that 'the findings suggest that evacetrapib could be administered with statins and may yield potentially clinically important incremental effects on lipoproteins'.

'However, development of drugs that increase HDL cholesterol levels has been challenging and fraught with failures,' the researchers noted.

Development of the first CETP inhibitor, torcetrapib, was terminated prematurely when the ILLUMINATE study revealed that it increased the risks of mortality and morbidity. Nevertheless, confidence is growing that other candidates, such as evacetrapib, anacetrapib and dalcetrapib, may be free of this effect.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases